story of the week
Early Disease Activity During Fingolimod Predicts Medium-Term Inefficacy in Relapsing–Remitting MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Multiple Sclerosis (Houndmills, Basingstoke, England)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Early Evidence of Disease Activity During Fingolimod Predicts Medium-Term Inefficacy in Relapsing-Remitting Multiple Sclerosis
Mult. Scler. 2020 Sep 25;[EPub Ahead of Print], L Ferrè, A Mogavero, F Clarelli, L Moiola, F Sangalli, B Colombo, V Martinelli, G Comi, M Filippi, F EspositoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.